CAR T-Cell Immunotherapy Named Advance of the Year in ASCO’s Clinical Cancer Advances 20

January 30, 2018 – A new and unique new way to treat cancer – chimeric antigen receptor (CAR) T-cell therapy – is poised to transform the outlook for children and adults with certain otherwise incurable cancers. ASCO named this type of adoptive-cell immunotherapy the Advance of the Year in its annual report. Released today in advance of World Cancer Day, Clinical Cancer Advances 2018 highlights the most impactful clinical cancer research and policy developments … (leggi tutto)